Research Reports

Summary

Avalo Therapeutics entered into a Milestone Buyout Option Agreement on April 26, 2026, modifying its $15 million contingent payment to former AlmataBio securityholders by requiring an immediate $2.25 million cash payment and granting Avalo a 90-day option to pay $5.125 million in cash or stock to fully satisfy the obligation, otherwise retaining a $12.75 million liability upon Phase 3 dosing.

Key takeaways

Avalo paid $2.25 million upfront to secure a 90-day option to buy out its $15 million milestone obligation — reducing potential future cash outflow by $9.875 million if exercised.

The $5.125 million buyout payment may be made in cash, common stock, or a combination, with stock priced at the 20-trading-day VWAP prior to issuance — introducing equity dilution risk if exercised.

If Avalo does not exercise the option within 90 days, it remains obligated to pay $12.75 million upon first patient dosing in any Phase 3 trial — preserving material contingent liability tied to clinical progress.

The agreement includes lock-up restrictions: shares issued as part of the buyout are subject to a 45-day transfer prohibition — limiting near-term liquidity for recipients.

Avalo must file a resale registration statement within 75 days if issuing stock, with liquidated damages of 1% per 30 days for filing or effectiveness delays — imposing compliance cost and penalty exposure.

Full analysis

This Milestone Buyout Option Agreement materially restructures Avalo’s contingent payment obligation arising from its March 2024 acquisition of AlmataBio. Originally, Avalo committed $15 million payable only upon the clinically uncertain event of first patient dosing in a Phase 3 trial — a milestone that could take years and carry significant development risk. Under the new terms, Avalo immediately pays $2.25 million and gains a 90-day window to elect full buyout for $5.125 million, effectively capping its maximum exposure at $7.375 million (versus $15 million) while converting a binary, high-risk contingency into a near-term, controllable outlay. The structure provides Avalo strategic flexibility: it preserves capital if clinical progress stalls, avoids dilution if paying cash, or manages balance sheet impact if using stock — though stock issuance triggers registration obligations and lock-up constraints. Critically, failure to exercise the option reinstates a $12.75 million liability tied directly to Phase 3 initiation, meaning clinical advancement now carries heightened financial consequence. The inclusion of liquidated damages for registration delays and the 19.9% beneficial ownership cap on stock issuance further underscore the complexity of equity-based settlement. For investors, this reflects both prudent liability management and increased near-term cash use — with implications for runway, dilution sensitivity, and confidence in the timing of AlmataBio-related clinical milestones.